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Introduction 13
The mini-chromosome maintenance 2-7 (MCM2-7) complex is a replicative helicase 14 that plays a central role in eukaryotic DNA replication (Bochman and Schwacha 2009; 15 Masai et al. 2010) . Its six subunits are evolutionally related with each other and form a 16 hetero-hexameric complex ( Figure S1 ). In the late M to G1 phase, the MCM2-7 17 hexamer is loaded onto replication origins bound with ORC1-6, to form pre-replicative 18 complexes (pre-RCs). This reaction, which is also known as licensing, is aided by 19 CDC6 and CDT1. Importantly, the MCM2-7 complex in pre-RCs is inactive as a 20
helicase. Subsequently, upon the activation of two essential kinases, S-CDK and 21 CDC7, MCM2-7 in pre-RCs is converted to the active CDC45-GINS-MCM (CMG) 22 helicase, which becomes the core of the replisome and drives the replication forks in 23 the S phase. The replication forks sometime stall or collapse when they encounter 24 obstacles of both intra-and extra-cellular origins, leading to the accumulation of 1 'replication stress' (Hills and Diffley 2014; Zeman and Cimprich 2014) . Failure or 2 incompletion in DNA replication causes genome instability, potentially resulting in cell 3 death, cancer development or genetic disorder. Moreover, cancer cells experience 4 replication stress intrinsically, which is thought to drive cancer evolution (Hills and 5 Diffley 2014). After DNA replication, unused MCM2-7 at dormant origins are removed 6 (Chong et al. 1995 ; Kubota et al. 1995; Todorov et al. 1995) . The meeting of two 7 converging forks during replication termination leads to the ubiquitylation of MCM7 in 8 the CMG helicase, which is recognized and extracted by the p97/CDC48 segregase 9 contrast, the levels of MCM2, 4 and 7 were mostly maintained throughout the time 1 course of the experiment. This notion was also confirmed in cells in which growth was 2 arrested by serum starvation (Figure S1B and C). These results show that MCM2-7 in 3 non-proliferating cells are relatively stable and suggest that MCMBP plays a role that 4 is related to cell proliferation. 5
6
To analyse the phenotype of MCMBP-deficient cells, we initially aimed to knockout the 7 MCMBP gene in HCT116 cells. However, the possible knockout cells obtained after 8 transfection formed small colonies and did not expand (data not shown). This is 9 consistent with the results obtained for fitness genes, as revealed by a CRISPR-based 10 forward screening (Hart et al. 2015) . Therefore, we generated a conditional MCMBP 11 cell line using the auxin-inducible degron (AID) technology ( Figure S2A ) (Nishimura et 12 al. 2009 ). We introduced a mini-AID and Clover (mAC) tag at the C-terminus of the 13 endogenous MCMBP in HCT116 parental cells constitutively expressing OsTIR1 from 14 the safe-harbour AAVS1 locus ( Figure S2B To test the impact of MCMBP depletion on cell proliferation, we treated the MCMBP-22 mAC cells with auxin and monitored their growth. The MCMBP-deleted cells showed 23 a growth defect 3 days after auxin addition compared with the mock-treated cells 24 ( Figure 2C ). We tested colony formation in the presence or absence of auxin and found 1 that MCMBP-depleted cells formed fewer and smaller colonies compared with the 2 mock-treated cells ( Figure 2D and E). To confirm that the proliferation defect was 3 caused by MCMBP depletion, we rescued the MCMBP-mAC cells by introducing an 4 MCMBP-expressing construct at the ROSA26 locus. The number of colonies formed 5 by the rescued cells was significantly increased, even though MCMBP-mAC was 6 depleted by the addition of auxin ( Figure 2E ). Furthermore, hTERT RPE1 and HeLa 7 cells with depletion of MCMBP by siRNA also showed proliferation defects, similar to 8 MCMBP-depleted HCT116 cells ( Figure S2C and D). hTERT PRE1 cells showed a 9 more pronounced defect that might have been caused by p53 activation following 10 DNA-damage accumulation (this will be shown and discussed later). Taken together, 11 these findings led us to conclude that MCMBP is important for the long-term survival 12 of human cells. 13
14
Two questions arose at this stage of the research: (1) why did the MCMBP-depleted 15 cells gradually become sick? And (2) what is the relationship between the control of 16 the expression of MCMBP and cell proliferation? MCMBP-mAC was rapidly depleted 17 within 6 h after auxin addition ( Figure 3A ). Interestingly, we noted that the expression 18 level of MCM2, 4 and 7 was gradually reduced 24 h after auxin addition in MCMBP-19 depleted cells. We confirmed this notion by microscopical examination of MCM5 and 20 7 in MCMBP-mAC cells treated with auxin for 5 days ( Figure 3B ). To clarify whether 21 MCMBP controls the expression of MCM2-7 at the mRNA level, we assessed the 22 mRNA levels of all MCM genes ( Figure S3 ). We found that the MCM mRNA levels 23
were not largely affected, supporting the idea that MCMBP maintains MCM expression 24 at the protein level. To generalize our finding that MCMBP maintains the expression of 1 MCM2-7 to other human cell lines, we depleted MCMBP by siRNA in hTERT RPE1 2 and HeLa cells and found that MCM2, 4, 5 and 7 were also reduced ( Figure 3C cells showed reduced expression of MCMs, we expected that the depleted cells would 13 experience replication defects caused by a reduced number of licensed origins. 14 Initially, we investigated origin licensing by looking at chromatin-bound MCM2-7 in the 15 G1 phase. For this purpose, the MCMBP-mAC cells were treated with or without auxin 16 before G1 arrest induced by lovastatin ( Figure 4A of -/+ auxin samples). This result indicates that the number of licensed origins is 23 reduced in MCMBP-depleted cells. Subsequently, we investigated cell-cycle 24 progression in MCMBP-depleted cells by flow cytometry and found that the depleted 1 cells accumulated in the late S to G2 phases ( Figure 4D ). We recapitulated this 2 phenotype by reducing MCM2 or MCM5 expression by siRNA while maintaining the 3 expression level of MCMBP ( Figure S4A and B) . These results strongly suggest that 4 MCMBP-depleted cells experience DNA replication defects because of reduced origin 5 licensing. Defects in DNA replication cause under-replication, leading to the generation 6 of DNA lesions in the following G1 phase (Lukas et al. 2011 ). We confirmed the 7 accumulation of DNA lesions in MCMBP-depleted cells by monitoring 53BP1 nuclear 8 bodies ( Figure 4E ). A study using xenopus egg extracts showed that MCMBP is 9 involved in MCM2-7 removal from chromatin DNA (Nishiyama et al. 2011 ). To test 10 whether this was also the case in human cells, the MCMBP-mAC cells were treated 11 with or without auxin before G2 arrest by a CDK inhibitor, RO-3306 ( Figure S4C and 12 D). The G2-arrested cells were lysed and the chromatin association of MCMs was 13 investigated. We found that chromatin-bound MCM2, 5 and 7 were down-regulated in 14 MCMBP-depleted cells because of the reduced expression of MCM2-7 ( Figure S4E ). 15
Because we did not observe accumulation of chromatin-bound MCMs, we concluded 16 that MCMBP is not important for MCM2-7 removal from chromatin DNA in human cells. 17
18
Our study demonstrated that MCMBP associated weakly with MCM4 and associated 19 mainly with MCM5, 6 and 7 monomers and/or subcomplexes, thus protecting them 20 from degradation ( Figure 4F ). This protective function is important to support the high 21 expression of MCM2-7 for maintaining genome integrity in proliferating cells. It 22 appears that the MCM2-7 hexamer is stable in non-proliferating cells (Figures 1D and 23 S1C). Conversely, the MCM subunits are highly synthesized in proliferating cells 24 (Leone et al. 1998; Ohtani et al. 1999 We did not observe an obvious re-localization of MCM2-7 to the cytoplasm after 11 MCMBP depletion in the human cells tested here (data not shown). However, we do 12 not rule out the possibility that MCMBP helps transport nascent MCM subunits from 13 the cytoplasm to the nucleus. Indeed, MCMBP contained a bipartite NLS ( Figure S1A Kusunoki and Ishimi 2014). We also found that overexpression of MCMBP caused 2 growth defects in human cells (data not shown). These results suggest that MCMBP 3 promotes both the assembly and disassembly of the MCM2-7 hexamer in the 4 nucleoplasm as a chaperone, and that the balance between MCMBP and the MCM 5 subunits is important for maintaining the pool of functional MCM2-7 hexamers ( Figure  6 4F). This hypothesis is supported by the observation that the expression level of 7 MCMBP was down-regulated in non-proliferating cells, in which the synthesis of the 8 MCM subunits is attenuated, whereas the expression of MCM2-7 was stably 9 maintained (Figures 1D and S1C) (Leone et al. 1998; Ohtani et al. 1999 ). We and 10 others noted that MCMBP also associates with MCM8 and 9, which form the MCM8-11 9 hexamer (data not shown) (Kusunoki and Ishimi 2014) . We predict that MCMBP is 12 also important for maintaining the expression of MCM8-9 for homologous 13 recombination repair in mitosis and meiosis (Lutzmann et according to the manufacturer's protocol. The transfected cells were cultured for 3 days 20 prior to analysis. 21
Protein extraction and Western blotting 22
Cells were collected using trypsin-EDTA and washed with D-PBS(-). Proteins were 23 extracted by adding RIPA buffer (25 mM Tris-HCl, pH 7.6, 150 mM NaCl, 1% NP-40, 24 1% sodium deoxycholate, 0.1% SDS and 1´ cOmplete-EDTA free). After suspension 1 and clarification by centrifugation, the supernatant was collected. Protein concentration 2 was checked using the Bradford reagent (Bio-Rad, #5000006) on a Smartspec 3000 3 instrument (Bio-Rad). SDS sample buffer (125 mM Tris-HCl, pH 6.8, 4% SDS, 20% 4 glycerol, 0.01% bromophenol blue and 10% 2-mercaptoethanol) was added and 5 samples were boiled for 5 min at 95°C. Proteins were separated on SDS-PAGE and 6 transferred to a Hybond ECL membrane (GE Healthcare) using Trans-Blot Turbo (Bio-7 Rad). After blocking with 1% skim milk in TBST for 1 h at room temperature, the 8 membrane was blotted using an appropriate antibody. Detection was performed using 9 a chemiluminescence system with the Amersham ECL Prime reagent (GE Healthcare) 10 or using a fluorescence-based system with ChemiDoc MP (Bio-Rad). 11
Antibodies 12
Listed in Table S1 . 13
Biochemical experiments 14
To fractionate cell extracts, cells were harvested and washed with D-PBS(-) before 15 resuspension in cytoskeletal (CSK) buffer (10 mM PIPES-KOH, pH 6.8, 100 mM NaCl, 16 300 mM sucrose, 1 mM EGTA and 1 mM MgCl2) supplemented with 1 mM DTT, 1´ 17 cOmplete EDTA-free (Sigma-Aldrich) and 0.5% Triton X-100. The suspension was 18 kept on ice for 20 min and vortexed periodically, to allow extraction. Whole-cell extracts 19
were collected at the end of the reaction and the remaining sample was centrifuged at 20 5000 rpm for 5 min at 4°C, to separate the supernatant (soluble fraction) from the pellet 21 (chromatin fraction). SDS sample buffer was then added to each fraction and the 22 samples were boiled at 95°C for 5 min. For size fractionation using a Superose6 23 column, 1.5 ´ 10 8 cells were harvested and washed twice with D-PBS(-) before re-24 suspension in IP buffer (20 mM HEPES-KOH, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 0.5% NP-40, 1 mM ATP and 5% glycerol) supplemented with 0.3´ PhosStop (Sigma-2 Aldrich) and 1´ cOmplete EDTA-free. The suspension was sonicated (80% duty cycle, 3 1.0 power, 5 s) using a Branson Sonifier 250 instrument. MgCl2 and benzonase 4 (Sigma-Aldrich) were added to the final concentrations of 5 mM and 150 U, 5 respectively. The suspension was kept on ice for 30 min, with occasional inversion. 6
The suspension was subsequently centrifuged at 5,600 rpm for 5 min at 4°C and the 7 supernatant was transferred to a new tube. This clarification process was repeated at 8 a centrifugation speed of 13,000 rpm. The cell extract was then filtrated using a 0.45 9
µm Spin-X centrifuge tube filter (Costar). At this point, 3/4 of the total cell extract was 10 separated for immunoprecipitation, while the remainder of the extract was fractionated 11 using Superose6 10/300GL (GE Healthcare) fitted to an AKTA explorer system (GE 12 Healthcare) in isocratic-elution manner with a fraction size of 200 µl. The collected 13 fractions were mixed with SDS sample buffer and boiled at 95°C for 5 min. The 14 remaining 3/4 of the total cell extract was subjected to immunoprecipitation. Antibody-15 conjugated bead preparation was performed as follows: 120 µl of DynaBeads Protein 16 G (ThermoFisher Scientific) was transferred to a tube and washed twice with IP buffer. 17
For conjugation, 800 µl of PBST (PBS with 0.05% Tween-20) and 12 µl of the FLAG 18 M2 antibody (Sigma-Aldrich) were added to the beads and rotated at room temperature 19 for 30 min. The coupled beads were washed with IP buffer once and blocked using 20 500 µl of 1% BSA in PBS for 30 min with rotation at room temperature. The beads 21
were then rinsed twice with IP buffer before incubation with the cell extract. The mixture 22 was rotated at 4°C for 2 h and the beads were rinsed with IP buffer containing 300 mM 23 NaCl three times, with 5 min of rotation each time. Proteins were eluted using 500 µl 24 of IP Buffer containing 0.25 mg/ml of the 3´Flag peptide (Sigma-Aldrich) and 1´ 1 cOmplete EDTA-free for 15 min at 4°C. The elution was fractionated using Superose6 2 10/300GL. 3
Cell-cycle synchronization 4
For synchronization at the G1 phase, asynchronously growing cells were treated with 5 20 µM lovastatin (LKT Laboratories) for 24 h. To induce G2 arrest, asynchronously 6 growing cells were treated with 9 µM RO-3306 for 16 h. 7
Flow cytometry 8
To analyse DNA content, cells were fixed overnight using 70% ethanol. After the 9 removal of the ethanol and subsequent wash with PBS, the cells were re-suspended 10 and stained with a propidium iodide (PI) solution (50 µg/ml of RNaseA, 40 µg/ml of PI 11 and 1% BSA) for 30 min at 37°C. Cells treated with BrdU for 30 min prior to harvesting 12 were fixed using 95% ethanol overnight. BrdU staining was performed as follows: after 13 the removal of ethanol and subsequent washing with PBS, the cells were treated with 14 2 M HCl containing 0.5% Triton X-100 for 30 min. To quench denaturing reactions and 15 calibrate pH, the cells were incubated in 0.1 M Na2B4O7 solution for 30 min to 1 h. 16
Subsequently, the cells were washed using Antibody Solution (1% BSA/PBS 17 containing 0.2% Tween-20). A mouse monoclonal anti-BrdU antibody (BD 18
Biosciences) was added to the antibody solution at 100´ dilution. For labelling, the 19 reaction was allowed to proceed for 1 h with gentle rotation. After washing, Antibody 20
Solution containing 1/100´ FITC-conjugated goat polyclonal anti-mouse IgG (Jackson 21 Laboratory) was added to the cells, which were incubated for 1 h with gentle rotation. 22
To remove non-specific binding, the cells were washed twice with Antibody Solution. 23
DNA was subsequently stained with PI, as described above. All samples were filtered 24 using a 42 µm nylon mesh cell strainer (Falcon) prior to analysis on a BD Accuri C6 1 flow cytometer (BD Biosciences). The acquired data were analysed using FCS 2 Express 4 Flow Cytometry Edition (De Novo Software) and the FlowJo software. were fixated with 3.7% formaldehyde in PBS for 15 min, permeabilized with 0.5% 7 TritonX-100 in PBS for 20 min, and blocked with 3% skim milk in PBS-T (0.05% 8
TritonX-100 in PBS) for 1 h. After blocking, the appropriate primary antibody (diluted 9 500´ in 1% BSA/PBS) was added onto the coverslip and incubated for 1 h, followed 10 by incubation with the appropriate secondary antibody (diluted 1000´ in 1% BSA/PBS), 11 in a similar manner. DNA was stained with 5 µg/ml of Hoechst33342 (Life 12 Technologies) for 30 min. All steps were performed at room temperature. Vectashield 13
Mounting Medium (Vector Labs) was then added onto the coverslip. All microscopy 14 was performed using a Delta Vision deconvolution microscope (GE Healthcare). 15
RNA detection 16
HCT116 MCMBP-mAC cells were seeded on 10 cm dishes and treated with or without 17 500 µM IAA for 5 days prior to harvest. Total RNA was isolated using Illustra RNAspin Table S2 . All data were 3 normalized to GAPDH (as a reference). 4 5 Acknowledgements 6
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Takahashi and Hiroyuki Sasanuma for discussion. We also thank Ms. Akemi treated with or without 500 µM IAA were fractionated for Western blotting using the 8 indicated antibodies. Note that MCMBP did not associate with chromatin (-auxin, Chr). 9 (D) HCT116 MCMBP-mAC cells were treated with or without 500 µM IAA for 3 days. 10
In the last 30 min of the incubation, 30 µM BrdU was added (prior to harvest). After 11 staining with an anti-BrdU antibody and PI, the cells were analysed by flow cytometry. 12
The quantification of late-S-phase cells is shown on the right. Error bars, standard error 13 (n = 3). (E) HCT116 MCMBP-mAC cells were treated with or without 500 µM IAA for 5 14 days. The cells were harvested and stained with an anti-53BP1 antibody. 
